Post by Biomed Industries Inc

Biomed Industries, Inc. Presenting Promising NA-921 Phase 2/3 Results for Rett Syndrome Treatment at EAPS 2025 Dr. Lloyd L. Tran, CEO, will present topline results of Phase 2/3 clinical trials of NA-921, a novel investigational treatment for Rett syndrome at the European Academy of Paediatric Societies (EAPS), October 18-20, 2025 in Lisbon, Portugal. His presentation summarizes the compelling proof of safety and efficacy for NA-921, an orally administered small molecule. Read more at: https://lnkd.in/gfRfn8AY #Rett